Plain-English translation of NCT06784726 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for patients with aggressive B-cell lymphoma that has come back or stopped responding to standard chemotherapy. The study gives patients this new antibody treatment for up to 12 months, and most participants will also receive CAR-T cell therapy (a type of immunotherapy using your own immune cells) after the first two months of treatment. Some patients may be able to skip the CAR-T step if their lymphoma responds very well to the medication alone.
Patients whose lymphoma returns or stops responding to initial treatment have limited options before moving to CAR-T cell therapy. This trial is exploring whether this new antibody medication can help shrink the cancer and improve outcomes before or instead of CAR-T, giving doctors another tool to fight aggressive lymphomas.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication on a schedule that starts with smaller doses in the first cycle, then increases to weekly infusions for the next three cycles (each cycle is 3 weeks long). After two months of treatment, you'll undergo a procedure to collect immune cells from your blood, followed by preparation (chemotherapy) and CAR-T cell infusion according to standard care. During the study, you'll have regular imaging scans, blood tests, and possibly biopsies to monitor how well the treatment is working. Your participation continues for up to 12 months of treatment, with follow-up visits extending to 5 years total to track your long-term health.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States